Health-related quality of life after oral cancer treatment: 10-year outcomes



Simon N. Rogers, FDS, RCS, FRCS, MD, and Derek Lowe, MSc C.Stat^c

Objective. The aim of this study was to report 10-year health-related quality of life (HRQOL) outcomes after treatment of oral squamous cell carcinoma (OSCC).

Study Design. Cross-sectional HRQOL surveys collated over a 13-year period for patients treated from 1992 yielded a cohort of 674 patients with OSCC who had undergone treatment with curative intent. HRQOL closest to 2 and 10 years was measured by using the University of Washington Quality of Life (UW-QOL) questionnaire.

Results. UW-QOL data were available for 67% (154) of 230 patients alive at 10 years. Three-quarters reported their overall quality of life (QOL) as good, very good, or outstanding. Free-flap surgery was the strongest predictor of overall QOL being less than good at 10 years. A significant problem or dysfunction, ranging from 7% to 13% across the 12 UW-QOL domains, was reported by a minority of patients. At the group level, the changes from 2 years to 10 years were minimal, with some improvement observed in appearance, chewing, mood and anxiety, and deterioration in swallowing. There was considerable scatter in individual changes over time.

Conclusions. At the group level, HRQOL at 10 years was similar to that at 2 years; however, at the individual-patient level, the domains were not so stable. (Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:144–149)

Health-related quality of life (HRQOL) is a key outcome of treatment for head and neck cancer (HNC). Although there are numerous publications in this field, there are only a few articles reporting on long-term HRQOL outcomes in HNC³⁻⁹ and even fewer reporting specifically on oral cancer. 10,11 The earlier literature has tended to consider "long term" in terms of several previous years after diagnosis and treatment; however, "late effects" has emerged as an important issue, so outcomes should be considered beyond 5 years. The importance of long-term outcomes and survivorship is reflected in national documents and initiatives for all cancers. Also, now there is better appreciation of late effects and how these might have an impact on HRQOL. 12

Bjordal et al.^{3,4} reported high levels of disease- and treatment-related symptoms, such as dryness in the mouth, mucus production, and psychological distress (30% of "cases" according to the General Health Questionnaire-20 [GHQ-20]), 7 to 11 years after radiotherapy for HNC. We have previously reported quality of life (QOL) 5 to 10 years after primary surgery for oral and oropharyngeal cancers; however, this was a small (48 patients) cross-sectional study.⁵ The findings of that study suggested that long-term survivors tend to

report good or excellent QOL, with outcomes similar to those at 1 year. This result is at variance with Mehanna et al., ⁷ whose cohort showed deterioration in overall QOL (life satisfaction) after 10 years, although those authors also had a small sample size and a cross-sectional design. Yan and coworkers ¹¹ reported QOL 8 years after oral cancer, in a prospective study with 30 long-term survivors. Clinically and statistically significant improvements between diagnosis and 8 years were seen with regard to pain, mood, and anxiety, whereas problems with chewing, speech, shoulder mobility, and taste worsened.

The findings from the small number of studies so far are inconclusive, and the aims of this study was to report the HRQOL outcomes at around 10 years and compare them with those reported at 2 years in a larger number of patients with oral cancer.

MATERIAL AND METHODS

Patients

The population comprised all patients presenting with oral squamous cell carcinoma (OSCC) at the Aintree University Hospital between January 1, 1992, and August 31, 2004. Patients treated with palliative intent, those with cognitive impairment, and those living overseas were excluded.

Statement of Clinical Relevance

With regard to long-term health-related quality of life after oral cancer, 10-year outcomes are very important when reporting the results of treatment. This is the first study to report large numbers and to be able to look specifically at difference between 2 years and 10 years.

© 2020 Elsevier Inc. All rights reserved.

2212-4403/\$-see front matter

https://doi.org/10.1016/j.oooo.2020.02.018

^aProfessor, Evidence-Based Practice Research Centre (EPRC), Faculty of Health and Social Care, Edge Hill University, St Helens Road, Ormskirk, UK.

^bConsultant Regional Maxillofacial Unit, University Hospital Aintree, Liverpool, UK.

^cProfessor, Medical Statistician, Director, Astraglobe Ltd, Congleton, Cheshire, UK.

Received for publication Dec 8, 2019; returned for revision Feb 16, 2020; accepted for publication Feb 25, 2020.

Volume 130, Number 2 Rogers and D. Lowe 145

Variables and measurements

The University of Washington Quality of Life (UW-QOL) questionnaire is a well-established one,² and from 1995, we have regularly used this to survey patients with OSCC at various stages after primary diagnosis. The UW-QOL version 4 questionnaire consists of 12 single-item domains, with 3 to 5 response options scaled evenly from 0 (worst) to 100 (best) according to response hierarchy. 13 UW-QOL domains are presented within 2 subscales: physical function and social-emotional function, as derived from an earlier work. 14 The physical function domain score is the mean of the appearance, swallowing, chewing, speech, taste, and saliva domain scores, whereas the social-emotional function score is the mean of the pain, activity, recreation, shoulder, and mood and anxiety domain scores. We computed the subscale scores if 4 or more domain scores were available, and published criteria were used to identify which patients had a significant problem or dysfunction.¹⁵ There is also a single-item overall QOL question on the UW-QOL version 4 questionnaire, for which patients are asked to consider not only physical and mental health but also other factors, such as family, friends, spirituality, and personal leisure activities important to their enjoyment of life.

For patients alive at 10 years, their UW-QOL record closest to 10 years was selected within a time window requirement, that is, at least 8 years on from the baseline (primary surgery or diagnosis if no surgery). All of these records were made after year 2000, and hence UW-QOL version 4 was used. To enable comparison of UW-QOL close to 2 and 10 years for patients alive at 10 years, their UW-QOL record closest to 2 years was selected within a time window of 12 to 36 months. Many patients with records close to approximately 2 years responded to earlier versions of the UW-QOL, in which the taste, saliva, mood, and anxiety domains, in particular, were absent.

Statistical analysis

Fisher's exact test was used to test for the association between baseline categories with survival at 10 years and overall QOL being less than good after 10 years. Responses to each UW-QOL domain were summarized into 3 categories: dysfunction, best possible response, and responses that fell between these 2 extremes. With regard to within-patient change data over time (2 and 10 years), McNemar's test (2 categories) or the McNemar-Bowker test (3 categories) was used to test paired table symmetry. Cohen's kappa coefficient was used to measure agreement in paired categorical data over time; values less than 0.20 reflect "poor" agreement; 0.21 to 0.40 "fair"; 0.41 to 0.60 "moderate"; 0.61 to 0.80 "good"; and greater than 0.80 "very good." The paired *t* test was used to compare paired numerical UW-QOL domain

scores over time, and 95% confidence intervals (CIs) for the mean change were computed. Wilcoxon's test was used to compare paired subscale scores.

This study was approved by the Aintree University Hospital Audit Department as part of annual surveys and data collected in routine care.

RESULTS

Table I shows the 674 eligible patients and their characteristics. Overall survival at 10 years was 34% (230 of 674; 95% CI 30.5%-37.8%). Baseline age, tumor staging, free-flap surgery, and primary treatment were associated (P < .001) with overall survival at 10 years (see Table I). UW-QOL data closest to 10 years (and at least 8 years on) was available for 67% (154 of 230), at a median (interquartile range [IQR]) of 121 months (range 117-125 months) from baseline. Free-flap surgery was the strongest predictor of overall QOL being less than good at 10 years (see Table I): 45% for patients with composite flaps, 26% for those with soft flaps, and 14% for those without free flaps. Other negative prognostic trends were observed for advanced tumors and for patients earlier in the cohort, although it was noted that the use of composite flaps fell from 25% in 1992-1996 to 12% in 2002-2004 and the use of any free flap from 81% to 64%.

A significant problem or dysfunction was indicated from the responses given by a minority of patients, ranging from 7% to 13% across the 12 UW-QOL domains (Table II). Otherwise, there was a fairly even split in patient response between the best possible response (35%–50% across domains) and being somewhere between the 2 extremes (33%–54%). Overall QOL was good or better for 74% (112 of 151) and subscale median scores of the median physical function and of the social—emotional function were 80 and 83, respectively (Table III).

Tables IV and V show the UW-QOL domain results for 113 patients with data close to 10 years (at least 8 years on) at a median (IQR) of 121 months (range 117–124 months) and close to 2 years (within 12–36 months) at a median (IQR) of 25 months (range 20–28 months). The main observation was that changes in the UW-QOL results were quite similar at 2 and 10 years with regard to the domain categorizations (see Table IV) and numerical mean domain scores (see Table V). Both tables indicate small improvements in appearance, chewing, mood, and anxiety and deterioration in swallowing. Within-patient Kappa agreement between categories at 2 and 10 years was generally fair to moderate, with slightly more agreement observed for the physical function domains than for

¹ Lines 204/205 of results. Their editing hasn't worked here, hence need to replace "...and subscale median scores of the median physical function and of the social-emotional function" with "...and subscale median scores of physical function and of social-emotional function"

August 2020

146 Rogers and D. Lowe

Table I. Baseline characteristics and overall quality of life (QOL) for those alive at 10 years

| | | Alive | e at 10 years | P value* | Overall Q | QOL less than good [†] | P value* | Median No. of months to UW-QOL questionnaire |
|--------------------|------------------------------|-------|---------------|--------------------|-----------|---------------------------------|----------|---|
| Baseline character | istics | % | n/N | | % | n/N | | 20 - 4 |
| | TOTAL | 34 | 230/674 | | 26 | 39/151 | | 121 |
| Year | 1992-1996 | 36 | 83/232 | .53 | 34 | 20/58 | .08 | 123 |
| | 1997-2001 | 35 | 94/269 | | 24 | 16/67 | | 121 |
| | 2002-2004 | 31 | 53/173 | | 12 | 3/26 | | 115 |
| Gender | Male | 32 | 137/426 | .18 | 25 | 24/95 | .84 | 121 |
| | Female | 38 | 93/248 | | 27 | 15/56 | | 122 |
| Age (years) | < 55 | 50 | 86/172 | < .001 | 32 | 19/60 | .39 | 123 |
| | 55-64 | 40 | 79/196 | | 21 | 12/58 | | 121 |
| | 65-74 | 28 | 47/169 | | 24 | 8/33 | | 119 |
| | 75+ | 13 | 18/137 | | | | | |
| Tumor site | Buccal | 28 | 38/134 | .02 | 37 | 10/27 | .08 | 123 |
| | Lower gum | 32 | 24/76 | | 25 | 3/12 | | 120 |
| | Tongue (anterior two-thirds) | 44 | 87/200 | | 20 | 11/56 | | 120 |
| | Floor of mouth | 32 | 69/215 | | 20 | 9/45 | | 121 |
| | Other | 24 | 12/49 | | 55 | 6/11 | | 123 |
| Overall clinical | Early (0-2) | 45 | 150/332 | < .001 excl. NK | 22 | 22/102 | .11 | 121 |
| stage | Late (3–4) NK | 24 | 80/339 0/3 | | 35 | 17/49 | | 121 |
| Primary treatment | Surgery alone | 45 | 166/367 | < .001 | 25 | 27/107 | .83 | 122 |
| | Surgery and RT | 24 | 59/241 | | 29 | 12/42 | | 121 |
| | Radiotherapy alone | 8 | 5/66 | | 0 | 0/2 | | 108 |
| Free flap surgery | Yes—composite | 27 | 45/169 | .001 | 45 | 13/29 | .01 | 123 |
| | Yes—soft | 38 | 103/271 | | 26 | 20/77 | | 122 |
| | No flap | 46 | 77/168 | | 14 | 6/43 | | 119 |
| Pathological stage | Early $(0-2)$ | 51 | 131/258 | < .001 | 20 | 18/88 | .06 | 122 |
| | • | | | excl. NK | | | excl. | |
| (surgical cases) | Late (3-4) | 28 | 93/333 | | 34 | 21/61 | NK | 121 |
| | NK | 6 | 1/17 | | 0 | 0/2 | | 105 |

NK, not known; QOL, quality of life; UW-QOL, University of Washington Quality of Life questionnaire.

the social—emotional function domains (see Table IV). The standard deviations (SDs) for individual change scores indicate considerable scatter between 2-year and 10-year scores (see Table V).

With regard to overall QOL being less than good, the agreement between the 2- and 10-year scores was weak (kappa statistic of 0.21) and the increase observed overall (from 14% [10 of 73] to 19% [14 of 73]) was not statistically significant (McNemar's test; P = .45). Median (IQR) physical function subscale scores were 74 (range 66–91) at 2 years and 78 (range 64–91) at 10 years (P = .50; Wilcoxon's paired test; P = .112); median (IQR) social—emotional function subscale scores were 83 (range 69–92) at 2 years and 83 (range 70–95) at 10 years (P = .39; Wilcoxon's paired test; P = .113).

DISCUSSION

There is a paucity of HRQOL data collected prospectively to 10 years after oral cancer. This is an important topic in respect to survivorship and late effects. Although our unit has published outcomes research on both HRQOL16 and survival after oral cancer, 17 longitudinal changes up to 10 years have not been reported before. Our longitudinal design allows comment on changes from 2 years to 10 years, and this study has the strength of being a relatively large sample of responders (154 patients) with 10year HRQOL data and an acceptable response rate (67%). The study has some limitations. First, the responses to the UW-QOL questionnaire was not collected at fixed time points during follow-up but as part of "annual" surveys, and hence the use of time windows to capture data close to certain time points. Second, with the aging patient population in the study, no attempt was made to account for other comorbidities, which might impact negatively on HRQOL. The sample is one of survivorship, with patients dropping out probably reporting worse HRQOL. Third, the cohort was inevitably historical

^{*}Fisher's exact test.

^{†151} of 230 alive at 10 years had overall QOL recorded from at least 8 years (96 months) on.

²Table 4, last row of results, the change P value. Given the way they have edited other P values then the value "0.27" should be ".27

Volume 130, Number 2 Rogers and D. Lowe 147

Table II. UW-QOL domain results for 154 OSCC patients alive at 10 years

| | | No. | Mean (SE) score | Dysfunct | tion | Somewho between | | Best resp | onse |
|--------------------|------------|-----|--------------------|----------|------|--------------------|----|-----------|------|
| UW-QOL—Physical | Appearance | 153 | 78.6 (1.6) | 10% | 16 | 53% | 81 | 37% | 56 |
| function subscale | Swallowing | 153 | 79.9 (2.2) | 12% | 19 | 34% | 52 | 54% | 82 |
| | Chewing | 151 | 71.9 (2.5) | 7% | 10 | 43% | 65 | 50% | 76 |
| | Speech | 153 | 81.1 (1.7) | 7% | 10 | 47% | 72 | 46% | 71 |
| | Taste | 152 | 74.6 (2.5) | 9% | 13 | 43% | 65 | 49% | 74 |
| | Saliva | 150 | 76.0 (2.3) | 10% | 15 | 44% | 66 | 46% | 69 |
| UW-QOL-Social- | Pain | 153 | 83.0 (1.8) | 9% | 14 | 37% | 56 | 54% | 83 |
| emotional function | Activity | 153 | 73.4 (2.0) | 12% | 19 | 50% | 77 | 37% | 57 |
| subscale | Recreation | 153 | 77.6 (1.8) | 7% | 11 | 54% | 82 | 39% | 60 |
| | Shoulder | 152 | 78.1 (2.4) | 13% | 19 | 33% | 50 | 55% | 83 |
| | Mood | 154 | 80.5 (2.0) | 12% | 18 | 39% | 60 | 49% | 76 |
| | Anxiety | 152 | 82.0 (1.8) | 9% | 13 | 39% | 59 | 53% | 80 |

Of the 230 alive at 10 years, 154 had UW-QOL data recorded from at least 8 years (96 months) on.

SE, standard error; UW-QOL, University of Washington Quality of Life questionnaire.

Table III. UW-QOL subscale scores and overall QOL at 10 years for patients with OSCC

| at 10 years for | patients with | obee |
|---------------------------------|-----------------|--------------|
| Physical function subscale scor | re (0-100): | |
| < 50 | 12% | 19/153 |
| 50-69 | 21% | 32/153 |
| 70-89 | 30% | 46/153 |
| 90-100 | 37% | 56/153 |
| Median (IQR) score | 80 (65-95 |), $N = 153$ |
| Social-emotional function subs | cale score (0-1 | 00): |
| < 50 | 9% | 14/154 |
| 50-69 | 16% | 24/154 |
| 70-89 | 40% | 61/154 |
| 90-100 | 36% | 55/154 |
| Median (IQR) score | 83 (70-95 |), $N = 153$ |
| Overall QOL: | | |
| Very poor/Poor | 7% | 10/151 |
| Fair | 19% | 29/151 |
| Good | 36% | 54/151 |
| Very good/Outstanding | 38% | 58/151 |
| Good or better | 74% | 112/151 |
| | | |

Of the 230 alive at 10 years, 154 had UW-QOL data recorded from at least 8 years (96 months) on.

Subscale scores were computed if 4 or more domain scores were available

IQR, interquartile range; *OSCC*, oral squamous cell carcinoma; *QOL*, quality of life; *UW-QOL*, University of Washington Quality of Life questionnaire.

(1992–2004), and various new treatment strategies have since emerged, such as intensity-modulated radiation therapy (IMRT), which could influence the long-term outcomes in the more recently treated patients.

Our sample does reflect survivorship in so much as there are relatively few patients 65 years of age or older at the time of treatment and who are alive after 10 years and contributing UW-QOL outcomes data, especially those age 75 years and greater. Similarly, those with advanced stages of disease, those who have had surgery and postoperative radiotherapy, and those requiring composite free tissue transfer are relatively fewer at longer-term follow-up than during treatment. This

might partly explain the relatively good survival rate and relatively consistent reported QOL characteristics between 2 and 10 years.

The long-term HRQOL outcomes that we have reported here appear to be relatively good across the UW-QOL domains with regard to dysfunction and high mean scores. Three-quarters of the patients stated that their overall QOL was good or better. Some domain scores, such as activity, chewing, taste and saliva, could be expected to fall naturally with age, but we could not explore this further as because normative data for the UW-QOL domains over time does not exist. ¹⁴

It is very difficult to directly compare the findings of this present study with those of previous studies because of the different case mix characteristics. Yan et al. 11 reported change in UW-QOL scores from 1 year to 8 years in 30 oral cancer survivors. In this period, patients reported clinically significant improvements in appearance, recreation, speech, saliva, and anxiety, whereas the scores of the other 7 items remained stable. In a crosssectional survey using the UW-QOL questionnaire, of the 26 patients, median age 14.7 years (range 3-27 years) after treatment for oral cancer when they were 40 years of age or less, 77% rated their overall QOL as outstanding, very good, or good. 10 Only radiotherapy seemed to adversely affect the overall QOL, and the key domains affected were appearance, mood, saliva, and shoulder function. Long-term outcomes with good to very good QOL were reported by 67 patients, 2 to 10 years after preoperative chemoradiotherapy followed by surgery, including microvascular reconstruction for advanced oral and oropharyngeal cancers.⁶ In contrast, a longitudinal assessment of 26 patients treated for advanced oral or oropharyngeal cancer, with a mean follow-up of 9.2 years (range 8-11 years), reported that a number of HRQOL domains worsened significantly (P < .01) in the long term: emotional functioning, social functioning, swallowing, speech, taste/smell, dry mouth, sticky saliva, and

 Table IV. UW-QOL dysfunction at 2 and 10 years

| | | No. at 2 and 10 years | | | 2 years | s | | | | | 10 years | ars | | | Change | Kappa coefficient of agreement (SE) between |
|--------------------|------------|--------------------------|-------------|------|----------------------|-----|------------------|----|-------------|-------|----------------------|-----------|------------------|----|----------|---|
| | | | Dysfunction | tion | Somewhere between | ere | Best response | əs | Dysfunction | ction | Somewhere between | here n | Best response | es | P value* | ine s categories over time |
| UW-QOL—Physical | Appearance | 101 | 10% | 10 | %09 | 61 | 30% | 30 | %8 | 8 | 54% | 55 | 38% | 38 | 80. | 0.32 (0.08) |
| function subscale | Swallowing | 112 | 2% | 9 | 36% | 4 | 55% | 62 | 13% | 15 | 33% | 37 | 54% | 9 | .03 | 0.43 (0.07) |
| | Chewing | 1111 | %9 | 7 | 25% | 19 | 39% | 43 | 2% | 9 | 47% | 52 | 48% | 53 | .12 | 0.42 (0.08) |
| | Speech | 112 | 3% | 3 | %19 | 89 | 37% | 41 | %9 | 7 | 52% | 58 | 42% | 47 | .18 | 0.55 (0.07) |
| | Taste | 77 | %6 | 7 | 36% | 28 | 25% | 42 | %9 | 5 | 43% | 33 | 51% | 39 | .38 | 0.54(0.09) |
| | Saliva | 73 | 14% | 10 | 41% | 30 | 45% | 33 | 11% | ~ | 44% | 32 | 45% | 33 | .21 | 0.59 (0.08) |
| UW-QOL—Social— | Pain | 107 | %8 | 6 | 33% | 35 | 26% | 63 | %8 | 6 | 34% | 36 | 28% | 62 | > .99 | 0.50 (0.08) |
| emotional subscale | Activity | 100 | 4% | 4 | 52% | 52 | 44% | 4 | %6 | 6 | 48% | 48 | 43% | 43 | .19 | 0.19(0.09) |
| | Recreation | 107 | %8 | 6 | 20% | 54 | 41% | 4 | 2% | 5 | 52% | 99 | 43% | 46 | .62 | 0.43 (0.08) |
| | Shoulder | 107 | 11% | 12 | 22% | 24 | %99 | 71 | 10% | 11 | 31% | 33 | 26% | 63 | .50 | 0.22 (0.08) |
| | Mood | 74 | 11% | ~ | 45% | 33 | 45% | 33 | 4% | 3 | 42% | 31 | 54% | 40 | .02 | 0.36 (0.09) |
| | Anxiety | 73 | 12% | 6 | 40% | 59 | 48% | 35 | 2% | 4 | 40% | 59 | 55% | 40 | 0.27 | 0.35 (0.09) |

SE, standard error; UW-QOL, University of Washington Quality of Life questionnaire. *McNemar-Bowker test.

coughing.⁸ However, this was a group of patients who had been treated with free flap reconstruction and postoperative radiotherapy, and this could account for the deterioration. In an assessment of 22 patients at 10 years after organ preservation treatment, long-term functional voice and speech problems were common, with fewer complaints in those treated with IMRT than in those treated with conventional radiotherapy, ¹⁸ as well as difficulty swallowing and reduced mouth opening. ¹⁹

When comparing overall HRQOL at 2 years and at 10 years in our sample, it was notable that in this cohort of patients, there was relatively little change at the group level. At most, the mean changes were in the order of 4 to 6 units. According to Kazis et al.²⁰ effect size can be obtained by dividing mean change by the SD in prechange data, and a "small" effect represents about 0.20 of SD, a "moderate" effect about 0.50 of SD, and a "large" effect about 0.80 of SD. Our results at 1 to 2 years gave domain SDs of around 20, and this indicates a "small" mean change being equivalent to 4 units, a "moderate" change being equivalent to 10 units, and a "large" change being equivalent to 16 units. Ringash et al.²¹ defined "minimal important difference" as the smallest difference that reflects a clinically important change in scores and stated that most published minimal important difference estimates fell into the range of 5% to 10% of the instrument range, which, for us, implied mean changes of about 5 to 10 units. Thus, it is reasonable to suggest that the changes between mean scores at 2 and 10 years we observed were small and just bordering on being clinically significant. There were improvements in appearance, chewing, mood, and anxiety and deterioration in swallowing. Although, in the whole cohort, HRQOL appeared relatively stable after 2 years, there were individual variations. Our data show considerable individual scatter in domain change scores (see Table V) and only fair to moderate agreement between 2 and 10 years with regard to the 3 categories (see Table IV, "dysfunction," "neither extreme," "best possible"). It is hard to ignore that in Table IV, there was no Cohen's kappa score greater than 0.60, which is the generally held criterion for defining good agreement, and thus, there was considerable within-patient instability between the results seen at 2 years and at 10 years.

CONCLUSIONS

In the long term, after oral cancer treatment, most patients report good or better overall QOL. Those alive at 10 years were considered survivors, with survival linked to the baseline characteristics, because those older and with advanced cancer were lost to follow-up. Group level changes between 2 and 10 years were small, with some bordering on being clinically significant, with improvements in appearance, chewing, mood, and anxiety and deterioration in swallowing. Changes at the individual-patient level were not so stable.

Volume 130, Number 2 Rogers and D. Lowe 149

Table V. UW-QOL mean domain scores at 2 and 10 years

| | | No. at 2 and 10 years | 2 years Mean (SE) | 10 years Mean (SE) | Change Mean (SD) | 95% CI: mean change | P value* |
|--------------------|------------|--------------------------|----------------------|-----------------------|---------------------|------------------------|----------|
| UW-QOL—Physical | Appearance | 112 | 74.3 (1.9) | 78.8 (1.8) | 4.5 (21.5) | 0.4, 8.5 | .03 |
| function subscale | Swallowing | 112 | 84.2 (1.9) | 79.9 (2.5) | -4.3(25.0) | -9.0, 0.4 | .07 |
| | Chewing | 111 | 66.2 (2.8) | 71.2 (2.8) | 5.0 (29.3) | -0.6, 10.5 | .08 |
| | Speech | 112 | 79.9 (1.6) | 80.1 (1.8) | 0.2 (17.3) | -3.1, 3.4 | .91 |
| | Taste | 77 | 80.4 (3.0) | 76.9 (3.3) | -3.5(22.7) | -8.7, 1.6 | .18 |
| | Saliva | 74 | 74.2 (3.4) | 74.3 (3.5) | 0.1 (24.6) | -5.6, 5.8 | .96 |
| UW-QOL-Social- | Pain | 113 | 83.2 (2.1) | 82.5 (2.2) | -0.7(18.8) | -4.2, 2.8 | .71 |
| emotional subscale | Activity | 112 | 77.5 (2.1) | 75.5 (2.3) | -2.0(24.7) | -6.6, 2.6 | .39 |
| | Recreation | 113 | 78.5 (2.1) | 79.6 (2.0) | 1.1 (21.2) | -2.9, 5.1 | .58 |
| | Shoulder | 110 | 81.3 (2.9) | 80.5 (2.6) | -0.8(27.8) | -6.1, 4.4 | .76 |
| | Mood | 74 | 79.0 (2.9) | 85.1 (2.3) | 6.1 (25.8) | 0.1, 12.1 | .05 |
| | Anxiety | 74 | 79.0 (2.9) | 84.2 (2.3) | 5.2 (24.6) | -0.5, 10.9 | .08 |

CI, confidence interval; SD, standard deviation; SE, standard error; UW-QOL, University of Washington Quality of Life questionnaire. *Paired t test.

ACKNOWLEDGMENTS

We thank the patients for contributing to this investigation through their completion of "annual" surveys.

DISCLOSURE

Although the study had no formal financial support, D.L. was funded by charitable donations to the HaNC (http://www.hancsupport.com/event/patient-research-forum).

REFERENCES

- Rogers SN, Semple C, Babb M, Humphris G. Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S49-S52.
- HaNDLE-onQoL. Available at: http://www.handle-on-qol.com/ Index.aspx. Accessed 8 December 2019.
- Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. *Int J Radiat Oncol Biol Phys.* 1994;28:847-856.
- Bjordal K, Kaasa S. Psychological distress in head and neck cancer patients 7-11 years after curative treatment. Br J Cancer. 1995;71:592-597.
- Rogers SN, Hannah L, Lowe D, Magennis P. Quality of life 5-10 years after primary surgery for oral and oro-pharyngeal cancer. *J Craniomaxillofac Surg*. 1999;27:187-191.
- Klug C, Neuburg J, Glaser C, Schwarz B, Kermer C, Millesi W. Quality of life 2-10 years after combined treatment for advanced oral and oropharyngeal cancer. *Int J Oral Maxillofac Surg*. 2002;31:664-669.
- Mehanna HM, Morton RP. Deterioration in quality-of-life of late (10-year) survivors of head and neck cancer. *Clin Otolaryngol*. 2006;31:204-211.
- Oskam IM, Verdonck-de Leeuw IM, Aaronson NK, et al. Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. *Oral Oncol.* 2013;49:443-448.
- Kovács AF, Stefenelli U, Thorn G. Long-term quality of life after intensified multi-modality treatment of oral cancer including intra-arterial induction chemotherapy and adjuvant chemoradiation. *Ann Maxillofac Surg.* 2015;5:26-31.
- Thomas L, Moore EJ, Olsen KD, Kasperbauer JL. Long-term quality of life in young adults treated for oral cavity squamous cell cancer. *Ann Otol Rhinol Laryngol*. 2012;121:395-401.
- Yan YB, Meng L, Liu ZQ, et al. Quality of life in long-term oral cancer survivors: an 8-year prospective study in China. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:67-75.

- 12. Murphy BA, Deng J. Advances in supportive care for late effects of head and neck cancer. *J Clin Oncol*. 2015;33:3314-3321.
- Rogers SN, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller E.A. Jr. The addition of mood and anxiety domains to the University of Washington quality of life scale. *Head Neck*. 2002;24:521-529.
- Rogers SN, Lowe D, Yueh B, Weymuller E.A. Jr. The physical function and social-emotional function subscales of the University of Washington Quality of Life Questionnaire. *Arch Otolaryngol Head Neck Surg.* 2010;136:352-357.
- Rogers SN, Lowe D. Screening for dysfunction to promote MDT intervention using the University of Washington Quality of Life questionnaire (UW-QOL). Arch Otolaryngol Head Neck Surg. 2009;135:369-375.
- Rogers SN, Hogg ES, Cheung WK, et al. "What will I be like" after my diagnosis of head and neck cancer? Eur Arch Otorhinolaryngol. 2015;272:2463-2472.
- Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer. Oral Oncol. 2009;45:201-211.
- Kraaijenga SA, Oskam IM, van Son RJ, et al. Assessment of voice, speech, and related quality of life in advanced head and neck cancer patients 10-years+ after chemoradiotherapy. *Oral Oncol.* 2016;55:24-30.
- Kraaijenga SA, Oskam IM, van der Molen L, Hamming-Vrieze O, Hilgers FJ, van den Brekel MW. Evaluation of long term (10years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer. *Oral Oncol.* 2015;51:787-794.
- Kazis LE, Anderson JJ, Meehan RF. Effect sizes for interpreting changes in health status. *Medical Care*. 1989;27:S178-S189.
- Ringash J, O'Sullivan, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. *Can*cer. 2007;110:196-202.

Reprint requests:

Simon N. Rogers
Consultant Regional Maxillofacial Unit
University Hospital Aintree
Liverpool
L9 1 AE
UK.
simonn.rogers@aintree.nhs.uk